CClinicalTrials.gg
Not yet recruitingNCT07851116Tissue SensorUpdated Oct 1, 2026

Tissue Sensor to Reduce the Need for Controlled Apnea During Retrograde Intrarenal Surgery

An interventional study of RIRS without Tissue Sensor and RIRS with Tissue Sensor in Tissue Sensor, sponsored by Botkin Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Botkin Hospital · Not applicable, Interventional, and Treatment

Updated Oct 1, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Retrograde intrarenal surgery is an established minimally invasive treatment for renal stones. During laser lithotripsy, respiratory motion causes the kidney, renal collecting system, and stone to move relative to the distal tip of the laser fiber. This can impair precise fiber positioning, reduce operative-field stability, and increase the risk of unintended laser exposure of the urothelium of the renal collecting system.

To reduce respiratory motion of the kidney, the surgeon may ask the anesthesiologist to temporarily pause mechanical ventilation. Controlled apnea can briefly stabilize the operative field; however, it requires interruption of ventilation and may cause oxygen desaturation, carbon dioxide accumulation, hemodynamic changes, and increased anesthetic burden.

Tissue Sensor is a technology that automatically terminates laser emission when contact between the distal tip of the laser fiber and tissue is detected. Tissue Sensor is expected to reduce the risk of unintended laser exposure of the renal collecting-system mucosa during respiratory motion of the kidney.

Greater surgeon confidence in the safety of laser activation may reduce the need to stabilize the kidney with controlled apnea. At the same time, brief automatic interruptions of laser emission may increase lithotripsy time and total operative time.

02

Conditions studied

  • Tissue Sensor
03

In context

Lead sponsor

Botkin Hospital is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 years or older.
  • A single renal stone.
  • An indication for elective RIRS.
  • Feasibility of performing the intervention with a flexible ureteroscope.
  • Recommended stone diameter on CT: 7-15 mm.
  • Stone located in a calyx, a group of calyces, or the renal pelvis.
  • Feasibility of TFL use.
  • General anesthesia with controlled mechanical ventilation.
  • No active urinary tract infection.
  • Ability to undergo low-dose non-contrast CT at 1 month.
  • Signed written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Multiple stones in the study kidney.
  • Complete or partial staghorn stone.
  • Ipsilateral ureteral stone.
  • Renal or upper urinary tract anomaly that substantially alters the anatomy.
  • Horseshoe, pelvic, or ectopic kidney.
  • Stone within a calyceal diverticulum.
  • Ureteral stricture.
  • Previous reconstructive surgery involving the study kidney or ureter.
  • Active infection, obstructive pyelonephritis, or urosepsis.
  • Nephrostomy drainage.
  • Pregnancy.
  • Severe respiratory failure or a contraindication to apnea.
  • Severe cardiovascular instability.
  • Inability to undergo general anesthesia.
  • Combined, bilateral, or percutaneous intervention.
  • Suspected upper urinary tract tumor.
  • Inability to comply with the study protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    patients with a single renal stone who are scheduled for elective retrograde intrarenal surger

    RIRS will be performed using a thulium fiber laser with Tissue Sensor activated. All automatic system trigger events will be recorded and, whenever possible, synchronized with the procedure video recording.

    Procedure: RIRS without Tissue Sensor · Procedure: RIRS with Tissue Sensor

Interventions

  • ProcedureRIRS without Tissue Sensor

    RIRS will be performed using the same TFL system with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the mucosa will be recorded from the procedure video.

  • ProcedureRIRS with Tissue Sensor

    RIRS will be performed using a thulium fiber laser with Tissue Sensor activated. All automatic system trigger events will be recorded and, whenever possible, synchronized with the procedure video recording. * total number of Tissue Sensor trigger events; * Tissue Sensor trigger events per minute of laser activation.

06

What researchers measure

Primary outcomes

  1. Proportion of patients requiring at least one episode of controlled intraoperative apnea during laser lithotripsy.

    Time frame: intraoperative

Secondary outcomes

  1. • number of apnea episodes;

    Time frame: intraoperative

  2. total apnea duration;

    Time frame: intraoperative

  3. mean number of apnea episodes per patient;

    Time frame: intraoperative

  4. maximum duration of a single apnea episode;

    Time frame: intraoperative

  5. minimum SpO2;

    Time frame: intraoperative

  6. incidence of desaturation;

    Time frame: intraoperative

  7. visible laser-induced mucosal

    Time frame: intraoperative

07

Study locations

No study locations are listed for this record.

08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07851116
Lead sponsor
Botkin Hospital
Responsible party
Malkhasyan Vigen Andreevich (Doctor of Medical science, Botkin Hospital) — Principal investigator
First posted
Oct 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Nov 2, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Nikita Astakhov
Contact
astakhov.nikita@inbox.ru
+8 (968) 490-46-72
Vigen Malkhasyan, Doctor of Medical Sciences
Contact
botkinhospital@zdrav.mos.ru
+79096441688

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion